← Joinn Laboratories(China)Co overview

Joinn Laboratories(China)Co vs Avantor: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Joinn Laboratories(China)Co (603127.CG)

Q3 2026
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

July 2026
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Latest
▲3▼1

Joinn profit surge and CRO sector rally drive gains

  • H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.

    This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.

  • Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.

    It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.

  • CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.

    It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.

  • Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.

    It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Avantor Inc (AVTR)

Q3 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

August 2026
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest
▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

  • Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.

    The guidance raise and beat are the core new event that changed the growth story.

  • Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.

    Order growth and book-to-bill are the forward-looking evidence behind the recovery.

  • APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.

    A concrete new market expansion that supports future demand.

  • Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.

    The main counterweight: profits are still squeezed even as revenue stabilizes.